ICM -Montpellier Cancer Institute ICM -Montpellier Cancer Institute 7 Department of Medical Oncology, Paoli Calmette Institute 8 Department of Medical Oncology, Paul Papin Cancer Centre 9 Department of Medical Oncology, Department of Radiation Oncology, ICM -Montpellier Cancer Institute, pp.17-18 ,
Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents, Cancer Treatment Reviews, vol.40, issue.1, pp.170-177, 2014. ,
DOI : 10.1016/j.ctrv.2013.06.008
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, Journal of Clinical Oncology, vol.26, issue.2, pp.242-247, 2008. ,
DOI : 10.1200/JCO.2007.12.4008
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, The Lancet, vol.376, issue.9747, pp.1147-54, 2010. ,
DOI : 10.1016/S0140-6736(10)61389-X
Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer, Journal of Medicinal Chemistry, vol.38, issue.13, pp.2463-71, 1995. ,
DOI : 10.1021/jm00013a022
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer, BJU International, vol.84, issue.9, pp.1241-1287, 2005. ,
DOI : 10.1016/0960-0760(94)90131-7
Abiraterone and Increased Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.364, issue.21, pp.1995-2005, 2011. ,
DOI : 10.1056/NEJMoa1014618
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, Journal of Clinical Oncology, vol.26, issue.7, pp.1148-59, 2008. ,
DOI : 10.1200/JCO.2007.12.4487
Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer, Steroids, vol.78, issue.9, pp.851-860, 2013. ,
DOI : 10.1016/j.steroids.2013.04.012
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment, Cancer, vol.72, issue.15 suppl, pp.968-75, 2014. ,
DOI : 10.1002/cncr.28518
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Annals of Oncology, vol.24, issue.7, pp.1807-1819, 2013. ,
DOI : 10.1093/annonc/mdt136
Humanized Bone Marrow Mouse Model as a Preclinical Tool to Assess Therapy-Mediated Hematotoxicity, Clinical Cancer Research, vol.17, issue.8, pp.2195-206, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-1959
Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301, European Urology, vol.67, issue.5 ,
DOI : 10.1016/j.eururo.2014.06.042
Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.31, issue.22, pp.312791-312799, 2013. ,
DOI : 10.1200/JCO.2012.45.4595
PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer, Clinical Genitourinary Cancer, vol.13, issue.1, pp.39-43, 2015. ,
DOI : 10.1016/j.clgc.2014.06.010
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer, Annals of Oncology, vol.25, issue.3, pp.657-62, 2014. ,
DOI : 10.1093/annonc/mdt581
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014. ,
DOI : 10.1056/NEJMoa1405095
Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012. ,
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer, European Journal of Cancer, vol.49, issue.18, pp.3821-3851, 2013. ,
DOI : 10.1016/j.ejca.2013.09.026
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?, Annals of Oncology, vol.23, issue.11, pp.2943-2950, 2012. ,
DOI : 10.1093/annonc/mds119
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer, European Urology, vol.66, issue.4, pp.646-52, 2014. ,
DOI : 10.1016/j.eururo.2014.01.018
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial, The Lancet Oncology, vol.15, issue.11, pp.1263-1271, 2014. ,
DOI : 10.1016/S1470-2045(14)70417-6